Imv Inc (NYSE:IMV) – B. Riley lifted their Q3 2019 EPS estimates for IMV in a research report issued on Monday, August 12th. B. Riley analyst M. Mamtani now anticipates that the company will earn ($0.08) per share for the quarter, up from their previous forecast of ($0.09). B. Riley currently has a “Buy” rating and a $11.00 target price on the stock. B. Riley also issued estimates for IMV’s Q4 2019 earnings at ($0.09) EPS, FY2019 earnings at ($0.34) EPS, FY2020 earnings at ($0.43) EPS, FY2021 earnings at ($0.62) EPS, FY2022 earnings at ($0.42) EPS and FY2023 earnings at ($0.05) EPS.
A number of other brokerages have also commented on IMV. Echelon Wealth Partners reiterated a “buy” rating on shares of IMV in a report on Tuesday, June 4th. Zacks Investment Research upgraded IMV from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a report on Wednesday. Raymond James set a $10.00 price target on IMV and gave the stock an “outperform” rating in a report on Monday. Finally, HC Wainwright restated a “buy” rating and issued a $11.50 target price on shares of IMV in a research note on Wednesday, June 12th. Five equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $8.81.
Institutional investors and hedge funds have recently modified their holdings of the business. Citadel Advisors LLC bought a new stake in shares of IMV in the second quarter valued at $37,000. Hartford Financial Management Inc. raised its stake in shares of IMV by 20.1% in the first quarter. Hartford Financial Management Inc. now owns 32,250 shares of the company’s stock valued at $129,000 after buying an additional 5,400 shares during the period. Ironwood Investment Management LLC bought a new stake in shares of IMV in the first quarter valued at $135,000. Bank of Montreal Can raised its stake in shares of IMV by 18.5% during the 1st quarter. Bank of Montreal Can now owns 75,661 shares of the company’s stock valued at $304,000 after purchasing an additional 11,807 shares during the period. Finally, Morgan Stanley raised its stake in shares of IMV by 260.5% during the 2nd quarter. Morgan Stanley now owns 90,368 shares of the company’s stock valued at $264,000 after purchasing an additional 65,300 shares during the period.
IMV Company Profile
IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Further Reading: What is a Futures Contract?
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.